Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 89

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 89
---
 of our 2024, 2023, 2022, 2021, and 2020 fiscal years. |

| (2) | The amounts reported in this column represent the amount of CAP to Mr. Blum, as computed in accordance with Item 402(v)(2)(iii) of Regulation S-K. The amounts do not reflect the actual amount of compensation earned by or paid to Mr. Blum during the applicable year. In accordance with the requirements of Item 402(v)(2)(iii) of Regulation S-K, the following adjustments were made to Mr. Blum’s total compensation for each year to determine the CAP: |

| Year |     |   Reported Summary 
 Compensation Table 
      Total for PEO |     | Reported Value of 
 Equity Awards(a)  |     |     Aggregate Equity 
 Award Adjustments(b) |     | Compensation Actually 
           Paid to PEO |
| 2024 |     |        $14,368,343 |     | $(12,860,027)     |     |         $(3,184,183) |     |          $(1,675,867) |
| 2023 |     |         $8,751,057 |     | $(7,425,000)      |     |          $19,357,681 |     |           $20,683,738 |
| 2022 |     |         $8,547,825 |     | $(7,408,750)      |     |           $7,554,056 |     |            $8,693,131 |
| 2021 |     |         $6,414,999 |     | $(5,276,600)      |     |          $18,722,367 |     |           $19,860,766 |
| 2020 |     |         $5,128,696 |     | $(4,075,200)      |     |           $9,935,312 |     |           $10,988,808 |

| (a) | Represents the reported value of equity awards as reported in the “Stock and Option Awards” column in theExecutive Summary Compensation Tablefor the applicable year. |

| 62 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS Pay Versus Performance

| (b) | The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant besides the difference in grant price and